Market Research

Market growth is driven by the global prevalence of infectious diseases & onset of COVID-19 and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements.

[263 Pages Report] The global infectious disease diagnostics market size is projected to reach USD 39.8 billion by 2026 from USD 28.1 billion in 2021, at a CAGR of 7.2%.

This study involved four major activities in estimating the current size of the infectious disease diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

Market Dynamics

• Global prevalence of infectious diseases and onset of COVID-19
• Rising focus on R&D and funding in infectious disease diagnostics
• Growing awareness for early disease diagnosis in developing countries
• Rising technological advancements in infectious disease diagnostics
• Shift in focus from centralized laboratories to decentralized POC testing

COVID-19 Impact on Global Infectious Disease Diagnostics Market

COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (CHINA) in December 2019, COVID-19 moved from a regional crisis to a global pandemic in just a matter of a few weeks. The COVID-19 pandemic negatively affected the overall sales of most of the companies but had an positive impact on the infectious disease diagnostics market because of the use of infectious disease diagnostic methods for COVID-19 testing. Lockdowns resulting from the COVID-19 pandemic caused people to delay undergoing health checkups, thus affecting the number of tests being performed and sales of reagents.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589

Based on product & service, the infectious disease diagnostics market is segmented into reagents, kits, and consumables; instruments; and software & services. In 2020, the reagents, kits, and consumables segment accounted for the largest share of this market. The frequent purchase of these products due to their recurrent usage drives the market growth of this segment.

The infectious disease diagnostics market is segmented into immunodiagnostics, polymerase chain reaction (PCR), clinical microbiology, isothermal nucleic acid amplification technology (INAAT), DNA sequencing & NGS, DNA microarrays, and other technologies. In 2020, the immunodiagnostics segment accounted for the largest share. This can be attributed to the increasing use of immunoassays in COVID-19 testing, POC infectious disease testing, the development of novel immunodiagnostic tests, and the rising trend of automation.

The geographical regions mapped in the report are:1. North America2. Europe3. Asia-Pacific4. Latin America5. Middle East & Africa

The global infectious disease diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the global infectious disease diagnostics market. The North American infectious disease diagnostics market’s growth can be attributed to the highly developed healthcare system in the US and Canada, the presence of many leading national clinical laboratories, and the easy accessibility to technologically advanced instruments.

Request for sample pages @  https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589

Some key players mentioned in the research report are:

• Abbott Laboratories (US)
• Roche Diagnostics Ltd. (Switzerland)
• bioMérieux SA (France)
• Thermo Fisher Scientific Inc. (US)
• Danaher Corporation (US)

According to the new market research report ” Drug Screening Market by Product (Consumables, Urine testing devices, Analytical, Breathalyzer, Chromatography) & Services, Sample Type (Urine, Breath), End User (Workplace, Laboratories, Criminal Justice, Hospitals) – Global Forecast to 2025″, published by MarketsandMarkets™ , global drug screening market is projected to reach USD 10.0 billion by 2025, from USD 4.5 billion in 2020, at a CAGR of 17.3%.

Major Growth Drivers:

Growth in this market is attributed to the rising drug & alcohol consumption, the enforcement of stringent laws mandating drug and alcohol testing, government funding in major markets, and regulatory approvals and product and service launches.

Expected Revenue Growth:

[192 Pages Report] The global drug screening market is projected to reach USD 10.0 billion by 2025, from USD 4.5 billion in 2020, at a CAGR of 17.3%.

COVID-19 impact on the drug screening market

COVID-19 has resulted in significant disruptions to businesses and economic activities globally and is expected to have a short-term negative impact on the drug screening market due to limited or non-availability of medical facilities/treatment centers, harm reduction service providers, and the fear of infection transmission. To reduce the strain on the healthcare system and decrease disease transmission, various governments worldwide provided guidelines to postpone or delay non-essential medical and surgical procedures.

Browse in-depth TOC on “Drug Screening Market”192 – Tables35 – Figures192 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162987773

The rapid testing devices segment will witness the highest growth during the forecast period.

Based on product, the drug screening market is segmented into analytical instruments, rapid testing devices, and consumables. Rapid testing devices market is further subsegmented into urine testing devices and oral fluid testing devices. The urine testing devices segment is expected to account for the largest market share in 2019. However, the oral fluid testing devices segment is projected to register highest CAGR during the forecast period. The high growth in this segment is attributed to the benefits it offers such as shorter detection window, non-invasive nature, and low risk of sample tampering.

North America was the largest regional market for drug screening market in 2019.

The drug screening market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2019, North America was the largest regional segment of the overall market, followed by Europe. The dominance of the North American market is attributed to factors such as rising consumption of illicit drugs, availability of government funding to curb drug abuse, and the presence of laws supporting drug screening, and growing burden of accidents due to unsafe levels of alcohol consumption.

Request for sample pages :  https://www.marketsandmarkets.com/requestsampleNew.asp?id=162987773

Key Market Players

The prominent players operating in this market include LabCorp (US), Quest Diagnostics (US), Alere (US), OraSure (US), Alfa Scientific Designs (US), Thermo Fisher Scientific (US), Drägerwerk (Germany), LifeLoc (US), MPD Inc. (US), Omega Laboratories (US), Premier Biotech (US), Psychemedics (US), Roche (Switzerland), Shimadzu (Japan), and Siemens Healthineers (Germany).

This market research study involved the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global biologics safety testing market.

[185 Pages Report] The global biologics safety testing market is projected to reach USD 6.2 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 12.4% during the forecast period.

The growth of the global biologics safety testing market is driven by factors such as the growth in the biologics and biosimilars markets, growing concerns over cell culture contamination, and rising biopharmaceuticals R&D activities and investments. In addition, emerging markets and increasing biopharmaceutical outsourcing are expected to provide significant growth opportunities for players in the Biologics safety testing market.

Market Dynamics

• Growth in the biosimilars and biologics markets
• Growing concerns over cell culture contamination
• Rising biopharmaceuticals R&D activities and investments
• Emerging markets offer lucrative opportunities
• Increasing biopharmaceutical outsourcing

Many companies are investing heavily in the development of biologics and biosimilars. Currently, more than half of the drug candidates in the discovery stage are biologics, such as proteins, peptides, and monoclonal antibodies. Biologics are expected to contribute around half of the revenue generated by the top 100 pharmaceutical products in the coming years.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144

Based on application, the biologics safety testing market is segmented into monoclonal antibodies manufacturing, vaccines manufacturing, blood and blood products manufacturing, cellular and gene therapy products manufacturing, and other applications. In 2020, the monoclonal antibodies manufacturing segment accounted for the largest market share. The large share of this segment can be attributed to the rising prevalence of diseases and increasing government initiatives for the development of monoclonal antibody drugs.

The geographical regions mapped in the report are:

North America accounted for the largest share of the biologics safety testing market in 2020. Rapid growth in the biopharmaceutical industry is the major factor driving the growth of the North American biologics safety testing market. Growing academic and government investments, rising demand for high-quality research tools for data reproducibility, increasing awareness among consumers about product safety, and the presence of major market players in this region are also driving the market for biologics safety testing in North America.

The major factors that are expected to be driving the high content screening market are need for cost containment in pharma R&D, growth in funding for cellular research, and technological advancements in HCS solutions are expected to support the growth of the HCS market during the forecast period

What the Market Looks Like?

[343 Pages Report] The anatomic pathology market is projected to reach USD 49.1 billion by 2026 from USD 35.1 billion in 2021, at a CAGR of 7.0%. The global anatomic pathology market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World (RoW). 

COVID -19 Impact on Anatomic Pathology Market

Globally, the COVID-19 outbreak has impacted every aspect of the diagnostics industry, including the anatomic pathology market. In the last few months, the number of patient visits to hospitals has reduced significantly, despite emergency and OPD services being available in hospitals.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137323145

The growth of the anatomic pathology market is majorly driven by the high incidence of cancer and other target diseases, recommendations for cancer screening, availability of reimbursement, and the growing focus on personalized medicine. In addition, emerging economies such as China, India, and Brazil are expected to offer significant growth opportunities for players operating in the anatomic pathology market during the forecast period.

What are Key Trends in the Market?

The growth of the Anatomic Pathology Market is primarily influenced by the following factors:

• High incidence of cancer and other target diseases
• Recommendations for cancer screening
• Availability of reimbursement
• Growing focus on personalized medicine
•  Increasing number of clinical trials pertaining to cancer drugs
• Emerging markets offer lucrative opportunities

Based on application, the anatomic pathology market is segmented into disease diagnostics and medical research. The disease diagnostics segment accounted for a larger share of the market in 2020 due to the rapid growth in the geriatric population and the increasing incidence of cancer and other chronic diseases.

Read more about Anatomic Pathology Market
@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=137323145

According to the new market research report “Oncology Nutrition Market by Cancer Type (Head & Neck, Stomach & Gastrointestinal, Liver, Pancreatic, Esophageal, Lung, Breast, Blood)“,published by MarketsandMarkets™, oncology nutrition market was valued at USD 1.34 Billion in 2017 and is expected to reach USD 2.21 Billion by 2023, at a CAGR of 8.7% during the forecast period.

Expected Revenue Growth:

[92 Pages Report] The oncology nutrition market was valued at USD 1.34 Billion in 2017 and is expected to reach USD 2.21 Billion by 2023, at a CAGR of 8.7% during the forecast period.

Objectives of the Study

• To define, describe, segment, and forecast the oncology nutrition market for different types of cancer
• To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, and industry-specific opportunities)
• To forecast the size of the oncology nutrition market, in four main regions —North America (along with countries), Europe (along with countries), Asia Pacific, and the Rest of the World
• To identify and profile key players in the global oncology nutrition market and comprehensively analyze their core competencies and market shares
• To track and analyze competitive developments such as mergers and acquisitions; new product launches; expansions; collaborations and agreements; and R&D activities of the leading players in the global oncology nutrition market

Major Growth Drivers :

Factors such as the development of elemental formulas and product innovation in terms of non-GMO-based formulas present significant opportunities for the growth of oncology-based nutrition formulas.

Accessories to Fuel the Growth of Oncology Nutrition Market

Factors such as shifting focus from parenteral to enteral nutrition, increasing incidence of cancer, growing demand for nutritional feeding in the homecare sector, rising number of patients being treated for malnutrition, and increasing quality of clinical research on nutritional interventions are driving the market growth.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=166703967

Browse in-depth TOC on “Oncology Nutrition Market”

11– Tables23 – Figures92 – Pages

The report analyzes the oncology nutrition market by type of cancer and region. Based on cancer type, the head and neck cancers segment accounted for the largest share of the market in 2017. Patients with head and neck cancers suffer from severe problems associated with oral nutritional intake.

Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=166703967

Geographically, the oncology nutrition market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2017, North America accounted for the largest share of this market. However, the Asia Pacific region is expected to witness the highest CAGR during the forecast period of 2018 to 2023. The growth of this segment can be attributed to the increased awareness and accessibility to advanced healthcare facilities, rising healthcare spending, large population base, and rapid improvements in the health insurance sector.

The major factors that are expected to be driving the high content screening market are need for cost containment in pharma R&D, growth in funding for cellular research, and technological advancements in HCS solutions are expected to support the growth of the HCS market during the forecast period

What the Market Looks Like?

[343 Pages Report] The anatomic pathology market is projected to reach USD 49.1 billion by 2026 from USD 35.1 billion in 2021, at a CAGR of 7.0%. The global anatomic pathology market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World (RoW). 

The global glycomics market is estimated to grow from USD 1.0 billion in 2020 to USD 2.0 billion by 2025, at a CAGR of 13.8%.

This study involved four major activities in estimating the current size of the glycomics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

Market Dynamics

• Increasing R&D Expenditure and Funding for Proteomics and Glycomics Research
• Growth of the Proteomics Market
• Technological Advancements in Glycomics Instrumentation

The market is categorized into five product segments, namely, enzymes, instruments, kits, carbohydrates, and reagents & chemicals. The enzymes segment is expected to dominate the market in 2020 and is projected to grow at the highest CAGR during the forecast period. The large share and high growth of this segment can be attributed to the consumable nature of enzymes and their wide applications in a variety of R&D and drug discovery procedures.

Download PDF Brochure@  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132685525

Based on application, the glycomics market is segmented into drug discovery & development, disease diagnostics, and other applications. Drug discovery & development is the largest and the fastest-growing application segment in the market, majorly due to the increasing R&D investments in pharmaceutical and biotechnology companies and the growing number of drug discovery research activities in academic research institutes.

The geographical regions mapped in the report are:1. North America2. Europe3. Asia-Pacific4. RoW5. Middle East & Africa

The global glycomics market is segmented into North America (US and Canada), Europe (Germany, the UK, France, Italy, Spain, and the Rest of Europe), Asia Pacific (Japan, China, India, Australia, and the Rest of Asia Pacific), and the Rest of the World (Latin America and the Middle East and Africa). In 2020, North America is expected to dominate the global market, followed by Europe. The largest share of North America is mainly attributed to increasing investments in glycomics research, rising R&D investments in pharmaceutical companies for drug discovery and the presence of all key players.

Request Sample Pages @  https://www.marketsandmarkets.com/requestsampleNew.asp?id=132685525

Some key players mentioned in the research report are:

The prominent players operating in the glycomics market include Merck KGaA (Germany), Agilent Technologies (US), Thermo Fisher Scientific (US), New England Biolabs (US), Shimadzu Corporation (Japan), Takara Bio (Japan), S-BIO (subsidiary of Sumitomo Bakelite Co. Ltd., Japan), Waters Corporation (US), Asparia Glycomics S.L. (Spain), Bio-Techne (US), Bruker Corporation (US), Danaher Corporation (US), RayBiotech (US), Z Biotech (US), Chemily Glycoscience (US), Dextra Laboratories (UK), Lectenz Bio (US), and Ludger Ltd. (UK)

This study involved four major activities in estimating the current size of the biomaterials market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=393

Market Dynamics

• Increased funds and grants by government bodies and universities for the development of novel biomaterials
• Increasing demand for implantable devices
• Growing demand for biomaterials in plastic surgery and wound healing applications
• Rising incidence of cardiovascular diseases
• Increasing research on regenerative medicine

The coronavirus outbreak disrupted business and economic activities globally in the first quarter of 2020. For instance, Aesthetic procedures, which mainly constitute cosmetic surgeries (like breast implantation and lipoplasty) and non-essential dental procedures, have been delayed due to the COVID-19 crisis. Moreover, From March to June 2020, the health system in the US experienced a significant decline in surgical volumes compared with the same period during the previous year.

Based on application, the biomaterials market is segmented into Cardiovascular, Orthopedic, Dental, Plastic Surgery, Wound Healing, Tissue Engineering, Ophthalmology, Neurological/CNS, and Other Applications. In 2019, the wound healing segment is expected to register the highest CAGR during the forecast period. Factors such as growing healthcare infrastructure, increasing diabetic population, vast population pool, in and the increasing healthcare spending will drive market growth.

Request for sample pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=393

The geographical regions mapped in the report are:

Geographically, the biomaterials market is segmented into North America, Europe, Asia Pacific, and Rest of the World. In 2019, North America accounted for the largest share of the biomaterials market, followed by Europe and the Asia Pacific. The large share of North America in the global market is attributed to the increase in biomaterial-based research, rising demand for plastic surgeries, growing incidence of cancer, and the rising prevalence of cardiovascular diseases.

Some key players mentioned in the research report are:

Key players in the biomaterials market include BASF SE (Germany), Covestro AG (Germany), Celanese Corporation (US), Corbion (Netherlands), Royal DSM (Netherlands), Evonik Industries (Germany), Carpenter Technology Corporation (US), Berkeley Advanced Biomaterials (US), Cam Bioceramics B.V. (Netherlands), CoorsTek Inc. (US), CeramTec (Germany), and Gelita AG (Germany).

The Inspection machines market is projected to reach USD 871 million by 2025 from USD 671 million in 2020, at a CAGR of 5.4% during the forecast period.

The growth of this market is majorly driven as companies are now increasingly adopting inspection systems throughout their production lines due to the growing concerns to the regulatory mandates introduced by the government and regulatory bodies in the healthcare industry to maintain compliance with Good Manufacturing Practices (GMP).

Market Dynamics

• Growing number of regulatory mandates to maintain compliance with GMP in the healthcare industry
• Increasing pharmaceutical & biotechnology R&D expenditure
• Growing product recalls
• The increasing number of inspection checkpoints throughout the production line
• Growth in the medical devices industry

The increasing adoption of automated inspection systems in the pharmaceutical and biotechnology industries, growth in the number of product recalls, an increasing number of inspection checkpoints throughout the production line, and technological advancements in inspection systems support the growth of the market.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=81453085

COVID-19 Impact on Global Inspection Machines Market

Since the beginning of 2020, the majority of the countries worldwide shut down their borders and limited transportation in a bid to contain the coronavirus (COVID-19) outbreak, thus, creating impediments for international trade and transportation. This had disrupted the supply chains for the inspection machines market, temporarily leading to a fall in demand due to uncertainty in the global economy and capital markets.

Additionally, we are estimating that the major share of the medical devices industry that includes imaging devices, dental care devices, and surgical products, among others, contributes to 60-75% of the overall medical devices market. This will have a stagnant or deep fall in the growth rate in 2020 and in a couple of quarters from 2021. A new, USD 5-7 billion market opportunity (by 2021) is opening up in the medical devices industry, including critical care medical devices. On the other hand, the impact of the pandemic on the pharmaceutical industry has been positive, with a steady increase in the manufacturing of nasal drug delivery technologies and the increasing focus on developing a vaccine

COVID-19 Impact on Global Inspection Machines Market

Since the beginning of 2020, the majority of the countries worldwide shut down their borders and limited transportation in a bid to contain the coronavirus (COVID-19) outbreak, thus, creating impediments for international trade and transportation. This had disrupted the supply chains for the inspection machines market, temporarily leading to a fall in demand due to uncertainty in the global economy and capital markets.

In 2019, North America accounted for the largest share of the inspection machines market, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The large share of this market segment can be attributed to the significant growth opportunities for players operating in the inspection machines market owing to the presence of a large number of pharmaceutical and biotechnology companies & medical device manufacturers in the region, stringent regulatory mandates for healthcare manufacturers, an increasing number of inspection checkpoints in the production line, and highly regulated inspection standards & obligatory compliance in the region.

Request for sample pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=81453085

The growth in Gas Chromatography Market is driven by the increasing adoption of GC-MS, rising crude & shale oil production, increasing importance of wastewater treatment, rising food safety concerns, and growing use of chromatography tests in the drug approval process.

[166 Pages Report] The global GC market size is projected to reach USD 3.5 billion by 2025 from USD 2.8 billion in 2020, at a CAGR of 4.1%.

“Adoption of GC systems is expected to increase during the forecast period.”

The systems segment of the GC instruments market is expected to account for the highest growth due to factors such increased capability to analyze complex compounds.

Market Dynamics

• Increasing crude & shale oil production
• Collaborations between chromatography instrument manufacturers and research laboratories/academic institutes
• Rising adoption of GC-MS
• Development of policies and initiatives to reduce environmental pollution levels
• Growing food safety concerns
• Growing importance of chromatography tests in the drug approval process

The Oil and Gas industry is growing at a CAGR of 4.1% in the end user market of GC. The growth is mainly attributed toincreasing crude & shale oil production and improved gas chromatography columns for the petroleum industry

Download PDF Brochure@   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=101656773  

On the basis of accessories and consumables, the GC market is divided into columns, columns accessories, autosampler accessories, flow management accessories, consumables & accessories, fittings & tubing, pressure regulators, gas generators, and other accessories. The columns segment is estimated to account for the largest share in the global gas chromatography market. The large share of this segment can primarily be attributed to factors such as improved gas chromatography columns for the petroleum industry.

The geographical regions mapped in the report are:1. North America2. Europe3. Asia-Pacific4. RoW

North America is expected to account for the largest share of the global GC market. Market growth in this region is driven primarily by the increase in R&D funding, cannabis research, market for shale oil and gas, and food and agricultural industry. On the other hand, the Asia Pacific is projected to have the highest growth rate during the forecast period. The high growth rate of the region can be attributed to factors such as extensive sales of generics in Japan and the growth in the pharma and biotech sectors in India and China.

Some key players mentioned in the research report are:

The major players in the global medical device reprocessing market are Stryker Corporation (U.S.), Johnson & Johnson (U.S.), Vanguard AG (Germany), Medline ReNewal (U.S.), Medtronic plc (Ireland), SteriPro Canada, Inc.(Canada), Pioneer Medical Devices AG (Germany), Vascular Solutions, Inc. (U.S.), HYGIA Health Services, Inc. (U.S.), ReNu Medical, Inc. (U.S.), SureTek Medical (U.S.), and Centurion Medical Products Corporation (U.S.).

Request for sample pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=101656773

Healthcare business process outsourcing allows healthcare facilities to contract their non-core activities to an external party and focus on their core competencies. Growth of this market is attributed to the growing outsourcing in the pharma and biopharma industries, need to curtail the escalating healthcare costs, rising demand for niche services (including care management and fraud detection services), and the need for structured processes and documentation in the healthcare industry.

What the Market Looks Like?

[309 Pages Report] The global healthcare BPO market is projected to reach USD 468.5 billion by 2026 from USD 296.4 billion in 2021, at a CAGR of 9.6% during the forecast period. North America dominated the healthcare BPO market, with a share of 49.0% in 2021, followed by Europe (30.6%) and the RoW (20.3%)

Cost savings form an important consideration in outsourcing, as by doing so, companies can reduce costs on resource management, labor, and space. There is pressure on the margins of healthcare payers due to the rise of health insurance exchanges (online marketplaces to obtain health insurance from competing providers) in the US. This enables consumers to obtain coverage from competing private healthcare providers and is likely to accelerate the adoption of outsourcing to rationalize costs.

Download PDF Brochure @   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=472 

COVID-19 Impact on the Healthcare BPO Market

The COVID-19 pandemic has had a significant impact on the world’s population and economy. As a result of the pandemic, healthcare facilities are facing immense pressure to create a well-coordinated environment where all clinical functions are connected internally and where the organization operates in coordination with other healthcare units. This is compelling healthcare organizations to outsource their non-core functions, including revenue cycle management, claims management, and patient engagement, among other functions, to third parties and focus on their core competencies for better patient outcomes. The impact of COVID-19 on the healthcare BPO industry is complicated as well as multi-faceted.

What are Key Trends in the Market?

The growth of the High Content Screening Market is primarily influenced by the following factors:

1. Shift to ICD-10 coding standards and upcoming ICD-11 standards
2. Pressure to reduce the rising healthcare costs
3. Loss of revenue due to billing errors
4. Demand for niche services
5. Need for structured processes and documentation
6. Lack of in-house expertise in end-use industries

Artificial intelligence and machine learning, in particular, make the drug discovery process more efficient and substantially improve success rates at the early stages of drug development. This will help healthcare BPO service providers to bring about major breakthroughs, as artificial intelligence also plays an important role in the discovery of drugs for chronic diseases such as cancer. Owing to its capabilities, AI significantly reduces the time taken to bring a cancer-combatting drug to the market, which will lead to significant growth in the healthcare BPO services market.

Read more about Healthcare BPO Market@  https://www.marketsandmarkets.com/requestsampleNew.asp?id=472 

[159 Pages Report] The North American nuclear medicine market is expected to reach USD 2.7 billion by 2024 from an estimated USD 2.2 billion in 2019, growing at a CAGR of 4.1% during the forecast period.

The study involved four major activities in estimating the current size for the North American nuclear medicine market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size.

Market Dynamics

• Increasing Incidence and Prevalence of Target Conditions
• Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
• Initiatives to Lessen the Demand-Supply Gap of Mo-99

The increasing adoption of automated inspection systems in the pharmaceutical and biotechnology industries, growth in the number of product recalls, an increasing number of inspection checkpoints throughout the production line, and technological advancements in inspection systems support the growth of the market.

Download PDF Brochure@   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1108 

Based on type, the market is categorized into diagnostic and therapeutic nuclear medicine. The therapeutic nuclear medicine segment is further segmented into alpha emitters, beta emitters, and brachytherapy isotopes.

The geographical regions mapped in the report are:

1. North America

2. US

3. Canada

Geographically, the North American market comprises of US and Canada. In 2018, the US accounted for the largest share of the nuclear medicine market. The large share can be attributed to the development of novel technologies for radioisotope production, government funding, and company initiatives in the country.

Based on application, the North American nuclear medicine market is segmented into SPECT, PET, and therapeutic applications. The SPECT applications segment is further segmented into cardiology, bone scans, thyroid applications, pulmonary scans, and other SPECT applications. The thyroid applications segment is projected to register the highest growth rate in the forecast period. The high growth of this segment can be attributed to the increasing incidence and prevalence of thyroid disorders.

Request for sample pages @  https://www.marketsandmarkets.com/requestsampleNew.asp?id=1108 

What the Market Looks Like?

[216 Pages Report] The global empty capsules market is projected to reach USD 3.7 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 7.2% during the forecast period.

Covid-19 Impact On The Global Empty Capsules Market

A mix of established pharmaceutical companies, as well as small startups have stepped forward to develop treatments and vaccines that target the infection caused by the novel coronavirus. Vaccine-related research activities in pharmaceutical and biotechnology companies, research centers, and academic research institutes are considered essential and have been largely unaffected in operations and output. Due to the increase in research activities, the availability of funding for research is expected to grow.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=218018190  

What Drives the Market?

The growth of the Empty Capsules Market is primarily influenced by the following factors:

• Increasing demand for nutraceuticals
• Expansion of capsule production in emerging countries
• Rising prices and lower availability of raw materials in the gelatin industry

Based on therapeutic applications, the empty capsules market is segmented into antibiotic & antibacterial drugs, dietary supplements, antacid & antiflatulent preparations, antianemic preparations (hematinic), anti-inflammatory drugs, cardiovascular therapy drugs, cough & cold drugs, and other therapeutic applications.

Request for sample pages @   https://www.marketsandmarkets.com/requestsampleNew.asp?id=218018190  

Recent Developments

• In 2021, Nutra’V TiO2 launched a new range of TiO2-free capsules. Available both in gelatin and HPMC and with excellent machinability, this range of capsules offers the best encapsulation solution for ingredient masking.
• In 2019, ACG acquired Xertecs, Xertecs develops and implements processes, products, and services for pharma companies across the globe. Its acquisition added to ACG’s capabilities.

According to the new market research report ” US Anticoagulation Therapy Market by Product ((Anticoagulants Drugs (NOACs, Warfarin)), PT/INR Devices (In-Office, Home Testing)), Service Type (Testing & Consulting), Type of Clinic (Hospital Associated, Independent & Pharmacy-based)”, published by MarketsandMarkets™ , US anticoagulation therapy market is projected to reach USD 27.83 Billion by 2022 from USD 17.25 Billion in 2016, at a CAGR of 8.5%.

The market is segmented into products (anticoagulation drugs and PT/INR testing devices) and anticoagulation clinics. The growth in the anticoagulation drugs market is primarily driven by the rising incidence of venous thromboembolism, atrial fibrillation, and stroke; long-term administration and high volume of recurring sales of anticoagulation drugs; and increasing demand for novel oral anticoagulants (NOACs).

Expected Revenue Growth:

[86 Pages Report] The US anticoagulation therapy market is projected to reach USD 27.83 Billion by 2022 from USD 17.25 Billion in 2016, at a CAGR of 8.5%.

Accessories to Fuel the Growth of US Anticoagulation Therapy Market :

In this report, the US anticoagulation therapy market is segmented on the basis of products and clinics. On the basis of products, the market is segmented into anticoagulation drugs and PT/INR testing devices.

Browse in-depth TOC on “US Anticoagulation Therapy Market”

29 – Tables

25 – Figures

86 – Pages

Download PDF Brochure:   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=114158575  

Based on drug type, the anticoagulation therapy market for drugs is segmented into NOACs, warfarin (VKA), and other drugs. In 2016, the NOACs segment dominated the US anticoagulation therapy market for drugs. Due to the better safety and efficacy of NOACs as compared to traditional therapies, the adoption of NOACs is higher as compared to traditional drugs. In addition, key market players such as Portola Pharmaceuticals (received FDA approval for its NOAC Betrixaban in July 2017) are focusing on the development of NOACs in order to capitalize on the growth opportunities presented by this shift in market dynamics

The anticoagulation therapy market for PT/INR testing devices is segmented into in-office testing devices and home testing devices. The in-office devices segment dominated the US anticoagulation therapy market for PT/INR testing devices. The large share of this segment is mainly attributed to the large number of patients opting for in-office testing services.

Request Sample Report:   https://www.marketsandmarkets.com/requestsampleNew.asp?id=114158575  

C. H. Boehringer Sohn (Germany), Bristol-Myers Squibb (US), Johnson & Johnson (US), Pfizer (US), Daiichi Sankyo (Japan), and Portola Pharmaceuticals (US) are the major market players in the global market for drugs while Roche (Switzerland), Abbott (US), Siemens (Germany), Alere (US), and CoaguSense (US) are the major market players in the US anticoagulation therapy market for PT/INR home testing devices.

Growth in this market is primarily driven by the increasing incidence of preventable chronic diseases, the need to control healthcare costs, rising focus on preventive healthcare, and rising investments in digital therapeutics.

What the Market Looks Like?

MarketsandMarkets forecasts the global digital therapeutics market is projected to reach USD 13.1 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 31.4% during the forecast period. The digital therapeutics market is segmented into North America, Europe, the Asia Pacific, and the RoW. In 2020, North America held the largest share of the market, followed by Europe.

Covid-19 Impact on the Digital Therapeutics Market

The impact of the coronavirus pandemic and the subsequent establishment of nationwide lockdowns is visible in various industries. The overall growth of various sectors has been heavily impacted, especially in countries with a high incidence rate of COVID-19, such as India, China, Brazil, the US, and several European countries (including Russia, Italy, and Spain). While industries such as oil and petroleum, aeronautics, and mining are experiencing a steep fall in revenues, the healthcare, biotechnology, and pharmaceutical industries are optimizing this situation to serve a maximum number of patients and healthcare professionals.

Download PDF Brochure @   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51646724

What are Key Trends in the Market?

The growth of the Digital Therapeutics Market is primarily influenced by the following factors:

1. Increasing incidence of preventable chronic diseases
2. Rising focus on preventive healthcare
3. Need to control healthcare costs
4. Significant increase in venture capital investments

Based on application, the digital therapeutics market is segmented into preventive and treatment/care-related applications. The largest share is the treatment/care related applications. This segment is attributed to the growing incidences of chronic diseases, the rising economic burden of their treatment, and investments in digital therapeutics to encourage the development of cost-effective and scalable treatment platforms for these conditions.

Read more about Digital Therapeuticsg Market@   https://www.marketsandmarkets.com/requestsampleNew.asp?id=51646724

Intravenous (IV) therapy devices are used to administer liquid substances directly into a vein. They can deliver nutrients or medications such as insulin or other hormones, antibiotics, chemotherapy drugs, and pain relievers. Presently, many companies are developing various infusion devices capable of being integrated with alarm devices, monitoring devices, and data exchange systems.

[166 Pages Report] The overall IV equipment market is expected to grow from USD 10.07 billion in 2017 to USD 13.64 billion by 2022, at a CAGR of 6.2% from 2017 to 2022

The global burden of chronic diseases such as heart disease, stroke, cancer, chronic respiratory diseases, and diabetes is increasing rapidly. According to the World Health Organization (WHO) 2015, chronic diseases accounted for approximately 60% of the total reported deaths in the world. The proportion of the burden of chronic diseases (chronic non-communicable diseases) is expected to increase to 57% by 2020 from 46% in 2001.

Market Dynamics

1. Low Prices of Reprocessed Medical Devices
2. Pressure to Reduce Volume of Regulated Medical Waste

Increasing incidence of chronic diseases and rising geriatric population, a growing number of surgical procedures performed, rising demand for ambulatory infusion pumps due to the growing home care market, rising number of needlestick injuries and infections are the key factors driving the growth of this market

Download PDF Brochure @   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=78345313 

The geographical regions mapped in the report are:

1. North America
2. Europe
3. Asia-Pacific
4. Middle East and Africa
5. Latin America

The IV equipment market in APAC is expected to grow at the highest CAGR during the forecast period. The demand for IV equipment and accessories in the APAC region is majorly driven by factors such as the large population base in the region, rising geriatric population, rising incidence of chronic diseases, improving accessibility to advanced healthcare facilities, rising healthcare spending, growing penetration of health insurance, increasing demand for advanced technologies, growing investments in emerging APAC countries by key market players, and expansion of private-sector hospitals to rural areas.

Some key players mentioned in the research report are:

Some of the prominent players in the global IV equipment market are Becton, Dickinson and Company (U.S.), B. Braun Melsungen AG (Germany), Baxter Interanl Inc. (U.S.), Fresenius SE & Co. KGaA (Germany), ICU Medical, Inc. (U.S.), Smiths Medical (U.K.), C. R. Bard, Inc. (U.S.), Terumo Corporation (Japan), Moog, Inc. (U.S.), and AngioDynamics, Inc. (U.S.). These players adopted both organic as well as inorganic strategies such as product launches and enhancements, collaborations and agreements, acquisitions and grant to sustain in this market.